2025年度业绩快报公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 证券代码：688426 证券简称：康为世纪 公告编号：2026-010 江苏康为世纪生物科技股份有限公司 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审计，具体数据以江苏康为世纪 生物科技股份有限公司（以下简称"公司"）2025年年度报告为准，提请投资者注意投资风险。 一、2025年度主要财务数据和指标 单位：万元 ■ 注：1、本报告期初数同法定披露的上年年末数。 2、除列明以"元"为单位以及加权平均净资产收益率外，本报告期、上年同期所列数据均以"万元"为单 位。 3、以上财务数据及指标以合并报表数据填列，但未经审计，最终结果以公司2025年年度报告为准。 二、经营业绩和财务状况情况说明 （一）报告期的经营情况、财务状况及影响经营业绩的主要因素 1、经营情况 2、财务状况 报告期末，公司总资产151,054.23万元，较报告期初下降6.65%；归属于母公司的所有者权益135,524.12 万元，较报告期初下降7.54%。 3、影响 ...

格隆汇2月27日丨康为世纪(688426.SH)公布2025年年度业绩快报，报告期内，公司实现营业收入 19,304.82万元，同比上升53.36%；实现归属于母公司所有者的净利润-10,328.49万元，实现归属于母公 司所有者的扣除非经常性损益的净利润-13,482.32万元，均较上年同期减亏。 报告期内，尽管面临激烈的市场竞争，公司管理层通过对市场认真的研判，在巩固原有业务的同时，积 极开拓新业务。基因测序、基因合成等科技服务业务的快速增长是营业收入增长的重要推动力。另一方 面，公司通过提高运营效率，在营业收入出现大幅增长的同时，期间费用得到有效控制，未出现大幅上 升。其中，研发支出方面，公司通过优化研发资源配置，以市场为导向，聚焦优势项目，着力提升研发 效率，研发费用同比有所下降。 ...

Core Viewpoint - The article discusses a groundbreaking study that utilized ancient DNA technology to diagnose a rare genetic condition in prehistoric humans, revealing insights into early human social structures and the care of individuals with disabilities [2][4]. Group 1: Ancient DNA Analysis - A team of scientists successfully extracted and analyzed ancient DNA from the inner ear bones of two prehistoric human remains, revealing that the juvenile individual suffered from NPR2 gene-related acromesomelic dysplasia [3][7]. - This study marks the earliest confirmed genetic diagnosis in human history, specifically identifying a rare disease and familial genetic case [4]. Group 2: Genetic Findings - The analysis identified a homozygous mutation in the NPR2 gene in the juvenile, leading to significant skeletal development issues, while the adult individual exhibited a heterozygous mutation, explaining the absence of severe symptoms [7]. - The NPR2 gene's heterozygous mutation is also associated with short stature in the general population [7]. Group 3: Social Implications - Despite the challenges posed by her genetic condition, the juvenile individual survived into late adolescence, indicating that her community provided necessary care and support [10]. - This finding suggests a level of inclusivity and care for vulnerable individuals in prehistoric societies, offering valuable insights into early human social organization and values [10]. Group 4: Future Applications of Ancient DNA Technology - The study highlights the potential of ancient DNA technology in tracing the history of human genetic diseases, paving the way for understanding the burden and distribution of rare hereditary conditions in ancient populations [12]. - This "gene archaeology" approach could be applied to more archaeological samples, potentially providing new insights into the evolution of human genetic diseases and aiding modern rare disease research [12].

Core Viewpoint - The company 康为世纪 (688426.SH) expects to reduce its net loss for the year 2025 compared to the previous year, with projected net profit attributable to shareholders ranging from -1.12 billion to -914.41 million, reflecting a year-on-year reduction in loss of 28.91% to 41.83% [1] Financial Performance - The projected net profit attributable to shareholders, excluding non-recurring gains and losses, is expected to range from -1.43 billion to -1.23 billion, indicating a year-on-year reduction in loss of 20.64% to 31.90% [1] - The main reason for the performance change is attributed to the recovery phase of the life sciences and diagnostic reagent industry, along with the ongoing market expansion of new businesses that have not yet achieved economies of scale [1] Revenue Growth - The reduction in net loss is primarily due to an increase in main business revenue, with significant overall sales revenue growth during the reporting period [1] - The growth is mainly driven by the rapid expansion of the company's technology service businesses, including gene sequencing and gene synthesis [1]

Core Viewpoint - The company 康为世纪 (688426.SH) expects to reduce its net loss for the year 2025 compared to the previous year, with projected net profit attributable to shareholders ranging from -1.12 billion to -914.41 million, reflecting a year-on-year reduction in loss of 28.91% to 41.83 [1] Financial Performance - The projected net profit attributable to shareholders, excluding non-recurring gains and losses, is expected to range from -1.43 billion to -1.23 billion, indicating a year-on-year reduction in loss of 20.64% to 31.90% [1] - The main reason for the change in performance is attributed to the recovery phase of the life sciences and diagnostic reagent industry, along with the ongoing market expansion of new business which has not yet achieved economies of scale [1] Revenue Growth - The reduction in net loss is primarily due to an increase in main business revenue, with significant overall sales revenue growth during the reporting period [1] - The growth is mainly driven by the rapid expansion of the company's technology service businesses, including gene sequencing and gene synthesis [1]

Core Insights - The anniversary celebration and major project signing ceremony for the Overseas Returnees Town in Shanghai Fengxian took place, highlighting the town's focus on attracting high-quality enterprises and talent in key sectors like biomedicine and smart terminals [1] Group 1: Project Signings and Developments - Several high-quality enterprises signed agreements with the Overseas Returnees Town, marking the implementation of the "Six Policies" aimed at supporting returnees [1] - Two service platforms were officially launched: a high-grade experimental animal resource development and service platform, and a new materials research and development public service platform [1] - Three significant projects with total investments reaching hundreds of millions were signed, including an automated factory for low-speed functional unmanned vehicles, a new paradigm for "smart biomanufacturing" in the experimental animal industry, and semiconductor equipment development to break foreign monopolies [1] Group 2: Company Composition - Over 95% of the enterprises that have signed agreements to settle in the town are returnee enterprises [2]

Core Viewpoint - The article emphasizes the acceleration of innovation in the pharmaceutical and medical device industries in China, driven by supportive policies and a shift from generic to innovative drug development, which is expected to enhance the industry's quality and global competitiveness [2][3][5]. Policy Support for Innovation - Since 2020, numerous favorable policies have been introduced to improve the ecosystem for innovative drugs, focusing on research standards, review and approval systems, patent protection, and reimbursement mechanisms [2]. - The "14th Five-Year Plan" highlights the importance of supporting innovative drugs and medical devices, indicating their critical role in national health and economic development [3][5]. Clinical Trials and Market Dynamics - The number of clinical trials for innovative drugs in China has surpassed 1,900, outpacing the US, Europe, and Japan, reflecting a significant increase in research quality and efficiency [3][8]. - By 2024, 39 innovative drugs approved for the first time in China were domestically developed, increasing from 31% in 2020 to 42% in 2024, indicating a strong trend towards domestic innovation [3][5]. Medical Insurance and Payment Systems - The narrowing surplus of the national medical insurance fund has created a mismatch between the commercialization of innovative drugs and their approval timelines, necessitating improvements in the commercial insurance system [8][27]. - The "15th Five-Year Plan" aims to establish a multi-tiered medical insurance system, which is expected to enhance the role of commercial health insurance in providing payment support for innovative drugs [27][32]. Medical Devices and Technological Innovation - The approval of innovative medical devices has increased by 43% from 2016-2020 to 2021-2024, driven by improved regulatory mechanisms and support for high-end medical device innovation [10][13]. - The article notes that while domestic brands are gaining global competitiveness, the industry still faces challenges in achieving systematic original innovation and key technology breakthroughs [13][19]. Emerging Technologies - The application of AI and brain-machine interfaces in healthcare is progressing towards industrialization, with the establishment of preliminary frameworks for clinical applications and payment rules [14][18]. - The integration of high-quality data flow in healthcare is anticipated to enhance the clinical benefits of new technologies, improving resource utilization and patient outcomes [18][19]. Biomanufacturing Developments - The biomanufacturing sector in China is transitioning from a "follower" to a "runner" stage, with significant advancements in technology and policy support, laying a solid foundation for future growth [19][20]. - The article highlights the importance of focusing on high-value, environmentally friendly products, such as biodegradable materials, to expand market opportunities [22][26].

Core Insights - Shenzhen has transformed from a fishing village into a global technology innovation hub over 45 years, driven by its inclusive spirit and innovative culture [1] - The city has undergone three significant phases: the pioneering era (1979-1992), industrial upgrading (1992-2010), and innovation-driven development (2010-present) [2] - Shenzhen's population is characterized by a high percentage of immigrants, a young demographic, and a strong entrepreneurial spirit, contributing to its innovation ecosystem [3] Historical Transformation - Shenzhen served as China's "testing ground" for market economy reforms, introducing the "time is money, efficiency is life" motto [2] - The city shifted from processing trade to high-tech industries, with companies like Huawei and ZTE emerging as key players [2] - A comprehensive innovation ecosystem has been established, with R&D intensity projected to reach 6.46% by 2024 and leading the nation in PCT patent applications for 18 consecutive years [2] Demographic Characteristics - Over 70% of Shenzhen's registered population consists of migrants, fostering adaptability and creativity [3] - The average age of residents is 33, with a significant number of high-level talents and returnees from studying abroad [3] - Approximately 60% of enterprises are technology-based, with a strong presence of private firms, exemplified by Huawei's projected R&D investment of 179.7 billion yuan in 2024 [3] Success Factors - Institutional innovation has been pivotal, including the delegation of research management and the establishment of a national intellectual property protection demonstration zone [4] - The market-driven innovation ecosystem is characterized by a high concentration of innovative enterprises and collaborative efforts between leading companies and SMEs [4] - Shenzhen's global integration is facilitated by platforms like Qianhai and He Tao, attracting top research institutions and talent [4] Innovation Case Studies - Huawei has evolved into a global leader in ICT, investing over 1.4 trillion yuan in R&D over the past decade [6] - DJI has redefined the consumer drone market, holding over 70% market share globally, supported by Shenzhen's robust electronics supply chain [6] - BGI has become a leading genomics research institution, contributing significantly to global pandemic response efforts [6] Challenges - Shenzhen faces resource constraints, particularly in land use, with a development intensity of 50% [7] - There is an imbalance in talent structure, with a shortage of top scientists in certain fields [7] - The city must transition from "following" to "leading" in key technology sectors like integrated circuits and software [7] - Increased competition from cities like Hangzhou and Suzhou poses a risk to Shenzhen's innovation leadership [7] Strategic Recommendations - Enhance original innovation by increasing government investment in basic research and establishing more national laboratories [8] - Optimize the talent ecosystem by implementing programs to attract and retain top young scientists [8] - Deepen international cooperation to build a global innovation network, leveraging Shenzhen's strengths in hardware and digital technology [8] Policy Innovations - Shenzhen has introduced a series of policies to support businesses throughout their lifecycle, including the "Shen i Enterprise" platform [9][10] - Financial reforms such as the "Tengfei Loan" model aim to provide long-term financing for high-growth companies [10] - Talent policies have been upgraded to support various categories of talent, including subsidies for young professionals [10] Future Outlook - Shenzhen aims to lead in original innovation, particularly in quantum technology and brain science, with plans for significant industry clusters by 2030 [11][12] - The city seeks to strengthen the "Shenzhen-Hong Kong Innovation Community" and enhance cross-border research collaboration [11] - A commitment to sustainable development includes initiatives for carbon neutrality and green finance innovations [12] Conclusion - Shenzhen's narrative is one of courage, wisdom, and inclusivity, with a focus on continuous innovation and breaking down institutional barriers [13] - The city's future as a leader in "Chinese intelligence manufacturing" hinges on its ability to overcome technological challenges and maintain its innovative edge [13]

Core Viewpoint - Berry Genomics (000710.SZ) announced the establishment of a joint venture company, Henan Yiyuan Tongkang Gene Technology Co., Ltd., in Zhengzhou, Henan Province, to meet the operational needs of its subsidiary, Beijing Berry Genomics [1] Group 1: Joint Venture Details - The joint venture will have a registered capital of 1 million RMB, with Berry Genomics contributing 600,000 RMB for a 60% stake, while individual investor Li Wei will contribute 400,000 RMB for a 40% stake [1] - The initial capital will be used for rental and initial personnel expenses, with products and services including gene sequencing and AI services procured from Berry Genomics and its subsidiaries [1] Group 2: Future Capital Plans - The joint venture plans to increase its registered capital to no less than 50 million RMB based on business progress and expectations of all parties involved [1]

Core Viewpoint - Berry Genomics (000710.SZ) announced the establishment of a joint venture, Henan Yiyuan Tongkang Gene Technology Co., Ltd., in Zhengzhou, Henan Province, focusing on integrated genetic testing services for newborns and children [1] Group 1: Joint Venture Details - The joint venture will be co-funded by Berry Genomics' wholly-owned subsidiary, Berry Health, which will contribute 600,000 yuan (60% ownership), while individual investor Li Wei will contribute 400,000 yuan (40% ownership) [1] - The registered capital of the joint venture is set at 1 million yuan, primarily allocated for venue rental and initial personnel costs [1] Group 2: Business Operations - The joint venture aims to collaborate closely with public medical institutions and clinical medical enterprises in key regions such as Henan to provide genetic disease testing services [1] - Products and related services, including gene sequencing and AI intelligent services, will primarily be procured from Chengdu Berry Health Gene Technology Co., Ltd. and its subsidiaries [1] Group 3: Future Capital Plans - The joint venture plans to increase its registered capital to no less than 50 million yuan, depending on business progress and operational performance [1]